Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.


Clinical Trial Description

This is a phase1, randomized sequence of placebo, low-, mid- and high-dose CST-2032 in Subjects with cognitive impairment. Sixteen (16) subjects with cognitive impairment will be enrolled. The first subject enrolled will be dosed as a sentinel. If no significant safety issues are noted in the sentinel subject, the remaining subjects will be dosed starting 24 hours after the Day 4 dose for the sentinel subject. Subjects will have the option to attend all study visits as outpatients or be admitted for a 4-5-night confinement period at the research facility. Subjects will receive matching placebo for CTS-2032, 1mg, 3mg, and 9 mg CST-2032 two hours after a pre-administered dose of 3 mg CST-107 in a randomized sequence on Days 1, 2, 3 and 4. Cognitive assessments (CANTAB) and a verbal fluency test will be administered daily. If operationally feasible, subjects will also undergo arterial spin labeling (ASL) magnetic resonance (MRI) imaging of the brain on Days 1 and 4. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05033912
Study type Interventional
Source CuraSen Therapeutics, Inc.
Contact Vice President, Translational Science
Phone +1 650 475-2842
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date October 2021
Completion date May 2022

See also
  Status Clinical Trial Phase
Completed NCT00934531 - Donepezil and the Risk of Falls in Seniors With Cognitive Impairment N/A
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Completed NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression Phase 4
Completed NCT01212692 - Effects of Mental Stimulation in Patients With Mild Cognitive Impairment Phase 2
Recruiting NCT00544791 - The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment Phase 2
Not yet recruiting NCT04971096 - Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment N/A
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Terminated NCT02180529 - The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment N/A
Completed NCT02110043 - Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS N/A
Completed NCT01383161 - 18-Month Study of Memory Effects of Curcumin Phase 2
Completed NCT01299766 - Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment Phase 3
Recruiting NCT04748666 - PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia N/A
Recruiting NCT03138018 - Aging Stereotypes and Prodromal Alzheimer's Disease N/A
Withdrawn NCT01891383 - Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Recruiting NCT03448055 - Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health N/A
Completed NCT01044758 - Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) Phase 2
Enrolling by invitation NCT05014893 - Neural Mechanisms of Cognitive Assessment and Rehabilitation for Mild Cognitive Dysfunction N/A
Completed NCT01061489 - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment N/A